Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS denies coverage for Menaflex

This article was originally published in The Gray Sheet

Executive Summary

Medicare agency issues national non-coverage decision May 25 for ReGen Biologics' Menaflex collagen knee meniscus implant, in-line with a February CMS proposal concluding the device did not improve health outcomes and is therefore not reasonable and necessary (1"The Gray Sheet" March 1, 2010). FDA is expected to conclude a re-review of preclinical and clinical data used to support Menaflex' 510(k) clearance within the next few weeks (2"The Gray Sheet" March 29, 2010)
Advertisement

Related Content

With Panel Advice In, FDA To Conclude Menaflex 510(k) Re-Review In Weeks
Medicare In Brief
Medicare In Brief

Topics

Advertisement
UsernamePublicRestriction

Register

MT028931

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel